← SynDRA
MOTESANIB
SynDRA canonical compound SYN0020054 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | KIT |
|---|
| Mechanism of action | VEGFR inhibitor |
|---|
All known targets
- KDR
- FLT1
- FLT4
- KIT
- PDGFRA
- RET
- PDGFRB
- TERT
Mechanisms of action (all sources)
- KIT INHIBITOR
- PDGFR inhibitor
- VEGFR inhibitor
- Stem cell growth factor receptor inhibitor
- RET INHIBITOR
- Tyrosine-protein kinase receptor RET inhibitor
- FLT1 INHIBITOR
- Vascular endothelial growth factor receptor inhibitor
- FLT4 INHIBITOR
- KDR INHIBITOR
- PDGFRB INHIBITOR
- Platelet-derived growth factor receptor inhibitor
Drug classes
- Protein Kinase Inhibitors
Cross-references
Synonyms
- AMG 706
- N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide
- N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide
- AMG-706
- N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide
- AMG706
- N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4- ylmethyl)amino]pyridine-3-carboxamide
- Motesanib [USAN]
- N-(2,3-Dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide
- U1JK633AYI
- CHEBI:51098
- Motesanib (USAN)
- 453562-69-1 (free base)
- N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
- 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-
- Motesanib [USAN:INN]
- UNII-U1JK633AYI
- N-(3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide
- AMG706/ Motesanib
- MOTESANIB [INN]
- MOTESANIB [MI]
- Motesanib (AMG-706)
- MOTESANIB [MART.]
- MOTESANIB [WHO-DD]
- SCHEMBL187470
- CHEMBL572881
- GTPL5660
- BDBM24773
- DTXSID10196488
- EX-A487
- cid_11667893
- BCPP000407
- HMS3244A09
- HMS3244A10
- HMS3244B09
- HMS3265G19
- HMS3265G20
- HMS3265H19
Look up MOTESANIB in the interactive SynDRA portal →